A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Status:
Recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib;
APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant
cell lines. This study is to explore the safety and efficacy of the combination of APG-1252
and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment
naïve patients.